Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beijing Wantai Biological Pharmacy Enterprise Co Days Payable Chart
Beijing Wantai Biological Pharmacy Enterprise Co Annual Data
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beijing Wantai Biological Pharmacy Enterprise Co Days Payable vs Biotechnology Industry
Beijing Wantai Biological Pharmacy Enterprise Co Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beijing Wantai Biological Pharmacy Enterprise Co (SHSE:603392) has a Days Payable of 251.11 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Beijing Wantai Biological Pharmacy Enterprise Co and its competitors. This is 130% above median its historical median of 109.25. Over the past decade, Beijing Wantai Biological Pharmacy Enterprise Co's Days Payable has ranged from 68.34 to 200.63. According to the industry distribution chart, Beijing Wantai Biological Pharmacy Enterprise Co ranks #288 out of 701 companies in the Biotechnology industry, placing it in the top 41.1%.
Is Beijing Wantai Biological Pharmacy Enterprise Co's Days Payable too high?
Beijing Wantai Biological Pharmacy Enterprise Co's current Days Payable of 251.11 is 130% above median its 10-year median of 109.25. Over the past 10 years, this metric has ranged from a low of 68.34 to a high of 200.63. The Biotechnology industry median Days Payable is 113.36. Beijing Wantai Biological Pharmacy Enterprise Co's value of 251.11 is 121.5% above this industry median. Based on the distribution chart, Beijing Wantai Biological Pharmacy Enterprise Co ranks #288 out of 701 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Beijing Wantai Biological Pharmacy Enterprise Co has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Beijing Wantai Biological Pharmacy Enterprise Co's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Beijing Wantai Biological Pharmacy Enterprise Co ranks #288 out of 701 companies for Days Payable. This puts Beijing Wantai Biological Pharmacy Enterprise Co in the upper half of its industry. The industry median Days Payable is 113.36. Beijing Wantai Biological Pharmacy Enterprise Co's value of 251.11 is 121.5% above this benchmark. Historically, Beijing Wantai Biological Pharmacy Enterprise Co's own Days Payable has ranged from 68.34 to 200.63 over the past decade. While the company's 10-year median is 109.25 vs. the industry median of 113.36, Beijing Wantai Biological Pharmacy Enterprise Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.36, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beijing Wantai Biological Pharmacy Enterprise Co's current Days Payable of 251.11 is 121.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Beijing Wantai Biological Pharmacy Enterprise Co and its competitors. For the Biotechnology industry, the median Days Payable is 113.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beijing Wantai Biological Pharmacy Enterprise Co's current Days Payable is 251.11, which is 130% above median its own 10-year median of 109.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Wantai Biological Pharmacy Enterprise Co stock overvalued right now?
Based on GuruFocus' analysis, Beijing Wantai Biological Pharmacy Enterprise Co (SHSE:603392) is currently considered Possible Value Trap. The stock's GF Value™ is ¥42.09, compared to a current price of ¥29.20 — trading 30.6% below its estimated fair value. The current Days Payable is 251.11, which is 130% above median its 10-year median of 109.25 and 121.5% above the Biotechnology industry median of 113.36. Beijing Wantai Biological Pharmacy Enterprise Co's overall GF Score™ is 53/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Beijing Wantai Biological Pharmacy Enterprise Co (SHSE:603392), the current Days Payable is 251.11 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beijing Wantai Biological Pharmacy Enterprise Co (SHSE:603392) Overvalued in 2026?
Based on GuruFocus' analysis, Beijing Wantai Biological Pharmacy Enterprise Co stock appears to be undervalued.
The current stock price of ¥29.20 is trading 30.6% below its estimated GF Value™ of ¥42.09.
GuruFocus considers Beijing Wantai Biological Pharmacy Enterprise Co to be Possible Value Trap.
Key valuation signals for SHSE:603392:
Days Payable: 251.11 (130% above median its 10-year median of 109.25)
GF Value™: ¥42.09 vs. price of ¥29.20 (30.6% below fair value)
Industry Position: 121.5% above the Biotechnology median (#288 of 701)
No single metric tells the full story. See the SHSE:603392 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beijing Wantai Biological Pharmacy Enterprise Co Business Description
Beijing Wantai Biological Pharmacy Enterprise Co Ltd is engaged in research, development, production, and sales of in vitro diagnostic reagents, instruments, and vaccines. The company has two segments: Diagnostic and Vaccine. The Diagnostic segment develops and sells in vitro diagnostic reagents such as ELISA, colloidal gold, biochemical, and chemiluminescent kits, along with instruments including chemiluminescent analyzers, fluorescent analyzers, and nucleic acid purification systems. The Vaccine segment focuses on products like the hepatitis E vaccine, the bivalent HPV vaccine, and the nasal spray COVID-19 vaccine. It generates the majority of its revenue from the Diagnostic segment.
53GF Score
Get the complete analysis for SHSE:603392
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603392 has been successfully added to your 
